Rare Disease Day 2022: how can we improve research in rare diseases?
In a blog for Rare Disease Day 2022, Cheney Drew discusses the DOMINO-HD study, registered at the ISRCTN registry, which aims to provide new insights into… Read more »
Cheney Drew is a research fellow and senior trials manager for the Mind, Brain Neuroscience study portfolio at the Centre for Trials Research in Cardiff University. She has a background in pharmacological research, with particular reference to neurodegenerative diseases, having completed her PhD in Huntington’s disease.
Since transitioning to clinical research, Dr Drew a been involved in the development and delivery of trials aimed at evaluating interventions (non-pharmacological and novel advanced therapies) in people with Huntington’s disease and other neurological disorders including tuberous sclerosis and epilepsy.
Given the complex and experimental nature of advanced therapies, she is particularly interested in how participants are approached, informed and provide consent to involvement in these trials. This includes listening to the participant voice as a central tenet of trial design.
Since transitioning to clinical research, Dr Drew a been involved in the development and delivery of trials aimed at evaluating interventions (non-pharmacological and novel advanced therapies) in people with Huntington’s disease and other neurological disorders including tuberous sclerosis and epilepsy.
Given the complex and experimental nature of advanced therapies, she is particularly interested in how participants are approached, informed and provide consent to involvement in these trials. This includes listening to the participant voice as a central tenet of trial design.
Latest posts by Cheney Drew (see all)
- Rare Disease Day 2022: how can we improve research in rare diseases? - 24th February 2022